raising questions about FDA's drug approval and surveillance process
January 2005
A firestorm of press is raising questions about FDA's drug approval and surveillance process.
It started with the Vioxx revelations. Now an FDA insider is naming several more drugs with safety concerns.
Bextra (valdecoxib) might increase the risk of heart attack... similar to Vioxx. FDA was quick to add a contraindication for patients having bypass surgery. FDA also added a new "black box" warning about serious skin reactions.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote